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Summary 
TRIM5 proteins are intracellular host restriction factors that constitute a species-specific barrier 
to the infection by a broad spectrum of retroviruses. TRIM5 interferes with the retroviral life-
cycle at an early post-entry stage by binding to incoming capsid (CA) cores. In certain primate 
species, including rhesus macaques, African green monkeys and owl monkeys, TRIM5 potently 
blocks the infection by HIV-1. By contrast, human TRIM5 has only weak activity against 
HIV-1, but efficiently restricts N-MLV instead. 
TRIM5 is an innate immune sensor for the retrovirus capsid lattice 
We established a protocol for the purification of owl monkey (aotus) TRIMCyp that yielded 
protein amounts amenable to biochemical assays and crystallization trials. This protocol could 
also be adapted for the production of human and African green monkey TRIM5α. 
In a collaboration with Pertel et al. we demonstrate that TRIM5 mediates innate immune 
signaling in a fashion that can be either uncoupled or coupled from retroviral capsid recognition. 
This novel activity of TRIM5 was abolished by mutation or deletion of the RING E3 ubiquitin-
ligase domain. Using the recombinant owl monkey TRIMCyp and assembled HIV-1 CA 
cylinders in in-vitro ubiquitin assays alongside with cell-based infectivity assays we uncovered 
that TRIM5 cooperates with the E2 enzyme Ubc13-Uev1a to catalyze the formation of free 
K63-linked ubiquitin chains, which activate the TAK1 kinase complex and stimulate AP-1 and 
NF-κB signaling. Interaction with the HIV-1 capsid lattice greatly enhances the Ubc13-Uev1a 
dependent E3 activity of TRIM5 and challenge with TRIM5 sensitive retroviruses induces the 
transcription of AP-1 and NF-κB-dependent factors. 
Dissecting the HIV-1 Capsid Lattice into Distinct TRIM5 Binding Units 
To understand how TRIM5α senses the retroviral CA lattice on a molecular basis we 
characterized the direct interaction between TRIM5α and a collection of cross-linked CA 
oligomers that are engineered to mimic individual interfaces of the HIV-1 CA lattice. This 
selection of CA oligomers includes a known hexameric HIV-1 CA alongside with novel 
trimeric CAs cross-linked at the three-fold symmetric lattice interfaces. By measuring the 
binding affinities of these CA oligomers for the isolated rhesus TRIM5α B30.2 domain and 
comparing with the KDs for monomeric or wild-type dimeric CAs we show that TRIM5α has 
an increased affinity for CA constructs mimicking the three-fold and six-fold symmetric 
interfaces. Hence we conclude that TRIM5α binds to multiple CA subunits that may map to an 
overlapping lattice epitope located at the threefold axis including two neighboring hexamers. 
Overall architecture and mode of dimerization of TRIM proteins revealed by the TRIM20 
structure 
The crystal structure of a fragment encompassing the CC-L2 and B30.2 domains of the TRIM5α 
homolog TRIM20/pyrin shows for the first time that TRIM proteins dimerize in an antiparallel 
fashion forming an elongated structure with the N-termini of the two monomers placed 167 Å 
apart. This reveals the overall domain organization in TRIM proteins and based on this structure 
a full-length stereotype TRIM was modelled taking available TRIM5 structures as templates. 
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To prove that the TRIM20 structure also applies to TRIM5, we determined the low-resolution 
shape of a homologous human TRIM5α construct by SAXS. A preliminary SAXS envelope of 
the human TRIM5 CC-L2 and B30.2 domains is shown in the discussion of this thesis. 
In addition, a crystal contact between two neighboring TRIM20/pyrin dimers suggests the 
existence of TRIM tetramers which reveals a new mechanism how TRIM5 may self-assemble 
into hexagonal arrays upon recognition of a retroviral CA lattice.
Zusammenfassung 
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Zusammenfassung 
TRIM5 Proteine sind intrazelluläre Restriktions-Faktoren, welche einen Spezies-spezifischen 
Schutz gegen ein breites Spektrum von Retroviren bieten. TRIM5 wehrt Infektionen bereits in 
einer frühen Phase des retroviralen Lebenszyklus ab, indem es unmittelbar nach dem Virus-
Eintritt in die Wirtszelle an die virale Kapsid (CA) hülle bindet. Bei gewissen Primaten Arten, 
wie zum Beispiel Rhesus Makaken, Afrikanischen Grünmeerkatzen und Nachtaffen verhindert 
TRIM5 die Infektion mit HIV-1. Beim Menschen jedoch wirkt TRIM5 nur schwach gegen 
HIV-1. Stattdessen bewirkt das menschliche TRIM5 eine Abwehr gegen das N-tropische Maus 
Leukämievirus (N-MLV). 
TRIM5 ist ein Sensor des angeborenen Immunsystems für das retrovirale Kapsid Gitter. 
Wir etablierten ein Protokoll zur Reinigung von TRIMCyp aus Nachtaffen, welches 
ausreichende Mengen an Protein zur Durchführung von biochemischen Experimenten und 
Kristallisations Versuchen lieferte. Dieses Protokoll konnte auch zur Produktion von TRIM5α 
aus Afrikanischen Grünmeerkatzen oder dem Menschen angewendet werden. 
In Zusammenarbeit mit Pertel et al. weisen wir auf, dass TRIM5 angeborene Immun Signale 
auslöst. TRIM5 vermittelt diese Signale sowohl gekoppelt an der Erkennung retroviraler 
Kapside, als auch unabhängig davon. Diese neu entdeckte Aktivität von TRIM5 wurde 
aufgehoben wenn man die RING E3 Ubiquitin-Ligase Domäne mutierte oder entfernte. Anhand 
von zell-basierten Infektivitäts Versuchen und in-vitro Analysen mit Ubiquitin, rekombinantem 
TRIMCyp aus Nachtaffen und assemblierten CA Partikeln konnte aufgedeckt werden, dass 
TRIM5 zusammen mit dem E2 Enzym Ubc13-Uev1a die Bildung freier Ubiquitin-Ketten 
katalysiert, welche wiederum den TAK1 Kinasen Komplex aktivieren und dadurch AP-1 und 
NF-κB Signalwege stimulieren. Durch Interaktion mit dem HIV-1 Kapsid Gitter wird die 
Ubc13-Uev1a abhängige E3 Aktivität von TRIM5 massgeblich stimuliert und die Infektion mit 
TRIM5 sensitiven Retroviren löst die Transkription AP-1 und NF-κB-abhängiger Faktoren aus. 
Zerlegung des HIV-1 Kapsid Gitters in unterscheidbare TRIM5 bindende Einheiten. 
Um auf molekularer Ebene zu verstehen wie TRIM5 das retrovirale Kapsid Gitter erkennt 
haben wir die direkte Interaktion zwischen TRIM5 und einer Sammlung künstlich verbrückter 
HIV-1 Kapsid Oligomere charakterisiert. Diese Kapsid Oligomere wurden so konzipiert, dass 
sie individuelle Nahtstellen zwischen Kapsiden im assemblierten Gitter nachahmen. Die 
Sammlung verbrückter Kapside beinhaltet ein publiziertes HIV-1 Kapsid Hexamer sowie 
neuartige HIV-1 Kapsid Trimere, welche unterschiedlich an der dreifach-symmetrischen 
Schnittstelle des Kapsid Gitters verbrückt wurden. Indem wir die Bindungs-Affinitäten dieser 
Kapsid Oligomere für die isolierte B30.2 Domäne von Rhesus TRIM5α gemessen und mit den 
KDs für monomeres oder Wild-Typ dimeres Kapisid verglichen haben zeigen wir, dass Rhesus 
TRIM5α eine erhöhte Affinität für Kapsid Konstrukte vorweist, welche die dreifach- und 
sechsfach-symetrischen Nahtstellen des Kapsid Gitters imitieren. Daraus folgern wir, dass 
TRIM5α an multiple Kapside bindet, welche am wahrscheinlichsten ein überlappendes Epitop 
bilden, das die dreifach-symmetrische Achse und zwei benachbarte Hexamere beinhaltet.  
Zusammenfassung 
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Gesamtarchitektur und Art der Dimerisierung von TRIM Proteinen aufgedeckt durch 
die Struktur von TRIM20. 
Die Kristall Struktur eines Fragmentes, welches die CC-L2 und B30.2 Domänen des zu 
TRIM5α homologen TRIM20/pyrin beinhaltet zeigt zum ersten Mal, dass TRIM protein 
antiparallel dimerisieren und eine elongierte Struktur bilden in welcher die N-Termini der 
Beiden Monomere an entgegengesetzten Enden, 167 Å voneinander entfernt, zu liegen 
kommen. Dadurch wird die relative Domänen Anordnung in TRIM Proteinen aufgedeckt und 
basierend auf dieser Struktur haben wir ein Stereotyp Modell für voll-längen TRIM Proteine 
erstellt, indem bekannte TRIM5 Strukturen als Vorlage genommen wurden. Um zu beweisen 
dass die TRIM20 Struktur auch für TRIM5α zutrifft, haben wir die nieder-auflösende Kontur 
eines homologen TRIM5 Konstrukts mittels Kleinwinkel-Röntgenstreuungs Experimenten 
SAXS bestimmt. Eine vorläufig berechnete SAXS Hülle der CC-L2 und B30.2 Domänen des 
humanen TRIM5 ist in der Diskussion dieser Doktorarbeit aufgeführt.  
Zusätzlich, weist ein Kristall Kontakt zwischen zwei benachbarten TRIM20/pyrin Dimeren auf 
die Existenz von TRIM Tetrameren hin, was auf einen neuen Mechanismus für die Selbst-
Assemblierung von TRIM5 in ein hexagonales Gitter hinweist. 
Abbreviations 
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Abbreviations 
AIDS Acquired Immune Deficiency 
Syndrome 
CA Capsid 
CA-NC Capsid nucleocapsid fusion 
CC Coiled-coil domain 
CCR5  C-C motif chemokine 
receptor 5 
CD4 Cluster of differentiation 4 
cDNA Complementary DNA 
CsA Cyclosporine A 
CTD C-terminal domain 
CXCR4 CXC motif chemokine 
receptor 4 
CypA CyclophilinA 
dscDNA Double-stranded cDNA 
EIAV Equine infectious anemia 
virus 
Env Envelope Glycoprotein 
FIV Feline immunodeficiency 
virus 
HAART Highly active antiretroviral 
therapy 
HIV-1 Human immunodeficiency 
virus type 1 
HIV-2 Human immunodeficiency 
virus type 2 
IN Integrase 
LEDGF Lens epithelium-derived 
growth factor 
LINE1 Long interspersed element 1 
LTR Long terminal repeat 
MA Matrix protein 
MHC  Major histocompatibility 
complex 
NC Nucleocapsid 
Nef Negative Regulatory Factor 
N-MLV N-tropic murine leukemia 
virus 
NMR Nuclear Magnetic Resonance 
NOE Nuclear Overhauser effect 
nsSNP Non-synonymous single 
nucleotide polymorphism 
NTD N-terminal domain 
PIC Pre-integration complex 
RING Really interesting new gene 
RNAi RNA interference 
RT Reverse transcriptase 
RTC  Reverse transcription 
complex 
shRNA Short hairpin RNA 
SIV Simian immunodeficiency 
virus 
SIVagm SIV from African green 
monkeys 
SIVcpz SIV from chimpanzees 
SIVmac SIV from rhesus macaques 
SIVrcm SIV from red-capped 
mangabeys 
SIVtan SIV from tantalus monkeys 
TAR Trans-acting response 
element 
TRIM Tripartite motif protein 
Vpu Viral Protein Unique 
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1 Introduction 
1.1 The AIDS Pandemic and Discovery of the Restriction Factor TRIM5 
The Acquired Immune Deficiency Syndrome (AIDS) was first recognized as a new disease in 
1981 [1] and the causative retrovirus, now called human immunodeficiency virus type 1 (HIV-
1), was identified only a few years later [2,3]. Since then more than 75 million people have 
been infected by HIV worldwide and more than 36 millions have died from AIDS related 
diseases [4,5]. Meanwhile AIDS is known to be caused by either of two distantly related 
lentiviruses: HIV-1 or HIV-2, with HIV-1 being the pandemic virus. Although advances in the 
development of antiretroviral drugs have lowered death tolls, morbidity and mortality has 
remained high in developing countries due to limited access to preventive measurements and 
antiretroviral treatment. 
The reasons for the worldwide AIDS pandemic have been intensively studied and it’s only since 
a few years that an overall picture of its origins can be drawn. First clues came from the 
discovery of HIV-2 in patients from western Africa and its close relationship to a simian virus 
that caused immunodeficiency in captive macaques [6,7]. The subsequent finding of additional 
viruses in various different primates that were collectively termed simian immunodeficiency 
viruses (SIVs) laid the basis for tracing back the source of HIV. HIV-1 and HIV-2 were found 
to be close relatives to SIVs from chimpanzees and sooty mangabeys, respectively [8,9]. This 
indicated that AIDS had emerged as a consequence of cross-species infections with SIVs from 
primates (Figure 1). While SIVs appeared to be mostly nonpathogenic for their natural hosts, 
SIVmac caused AIDS in rhesus macaques. Later studies revealed that SIVmac too was 
generated accidently by zoonotic transfers of a simian virus after captive macaques had 
contacted blood or tissue samples from sooty mangabeys in an US primate center [10,11]. 
Studies on SIVcpz, the genetically closest relative to HIV-1, had for a long time been hampered 
by the endangered status of chimpanzees. Finally, the development of noninvasive diagnostic 
methods had allowed investigations on wild-living animals identifying the common 
chimpanzee as a natural reservoir for SIVcpz [12-15]. Infected animals showed many properties 
common to human HIV infections, including increased mortality, CD4+ T-cell depletion and 
similar routes of transmission [15,16]. Phylogenetic analysis of isolated viruses revealed that 
SIVcpz was generated by recombination of two SIVs, one resembling to SIVrcm in red-capped 
mangabeys and the other to a SIV lineage that infects several African green monkeys [17] 
(Figure 1). This implies that multiple cross-species transmissions had to take place and is further 
supported by the known hunting behavior of chimpanzees that includes killing of other 
monkeys, suggesting that they acquired SIV in the context of predation. 
Humans must have acquired the precursors of HIV-1 through mucosal exposure to infected ape 
blood or body fluids, which most commonly occurs with the consumption of raw meat [18]. 
HIV-1 is subdivided into four distinct lineages, termed groups M, N, O and P, with group M 
representing the pandemic form. Genetic analysis showed that each of these groups arose from 
an independent cross-species transmission event (Figure 1).  All four groups cluster with 
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SIVcpzPtt that infects the P.t. troglodytes subspecies of chimpanzees in central Africa and the 
ape precursors of groups M and N could even be traced back to particular P.t. troglodytes 
communities [13,14]. 
 
Figure 1: Origins of human AIDS viruses. Old World monkeys are naturally infected with 
more than 40 different lentiviruses, termed simian immunodeficiency viruses (SIVs) with a 
suffix to denote their primate species of origin (e.g., SIVsmm from sooty mangabeys). Several 
of these SIVs have crossed the species barrier to great apes and humans, generating new 
pathogens. Known examples of cross-species transmissions, as well as the resulting viruses, 
are highlighted in red (Figure & Legend taken from [19]). 
 
SIVcpzPtt had to counteract different host restriction factors in order to cross the species barrier 
to humans and become a productively infectious virus. Of the restriction factors that constitute 
a barrier to SIV cross-species transmissions, tetherin probably had the greatest impact on the 
precursors of HIV-1 and HIV-2. Tetherin is a transmembrane protein, which inhibits budding 
and release of virions from infected cells by “tethering” the released virions at the cell surface. 
SIVs inactivate tetherin either by using their Nef protein to remove it from the cell surface, or 
by using their Vpu protein to degrade it. Some viruses use their envelope glycoprotein to bind 
and inhibit tetherin. The human tetherin gene differs from its ape orthologs by a five codon 
deletion in the cytoplasmic domain rendering the SIVcpz Nef protein inactive on transmissions 
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to humans [20]. In the case of HIV-1 group M, this adaptive hurdle was overcome by alterations 
in the Vpu gene rendering the gene product potently active against tetherin [21]. 
While SIVs that coevolved with their natural hosts appear to be mostly nonpathogenic, multiple 
examples have shown that successful zoonosis can lead to the emergence of new SIVs that are 
pathogenic to their new hosts, causing immunodeficiency-like symptoms. This emphasizes the 
important role of host restriction factors in maintaining a barrier to cross-species transmissions 
of pathogens. 
HIV-1 is potently blocked in many Old World monkey species [22-28]. This is not the case in 
New World monkeys with the exception of owl monkeys: They restrict HIV-1, but are 
susceptible to SIV [26,29]. 
The finding that the block to HIV-1 was saturable at high virus titers and that restriction was 
dominant in cell-fusion experiments already suggested existence of a specific antiviral factor 
[23,24,28]. Finally, two independent approaches uncovered TRIM5 as the HIV-1 specific 
antiviral factor in old world monkeys and owl monkeys, respectively. The first approach 
screened a cDNA library from rhesus macaque cells for the ability to confer resistance to 
otherwise permissive human cells [30] identifying the α isoform of the TRIM5 gene products 
as the responsible restriction factor. The second approach was based on the observation that 
disruption of the CA-CypA interaction in owl monkey cells, either by cyclosporine, mutations 
or shRNAs targeting CypA, lead to suppression of anti-HIV-1 restriction activity. Surprisingly, 
reintroduction of CypA protein into shRNA expressing cells did not restore resistance to HIV-
1. A search for additional potential RNAi targets amongst owl monkey cDNAs uncovered a 
TRIM5-CypA fusion protein that was sufficient to transfer HIV-1 restriction activity to human 
cells [31,32]. 
1.2 The HIV Life Cycle and the Early Block to Retroviral Infection by TRIM5 
HIV-1 can persistently infect humans by evading the innate and adaptive immune systems, 
despite encoding only 15 mature proteins. HIV-1 compensates for this apparent simplicity by 
exploiting a myriad of cellular factors to replicate and conquers several host restriction factors 
that fight to suppress its replication [33]. The HIV-1 life cycle can be divided into an early 
phase that occurs between viral entry into the host cell and integration into its genome, and a 
late phase that comprises the transition from the state of integrated provirus to full viral 
replication [34]. 
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Figure 2: Schematic depiction of a mature HIV-1 virion. The infective mature HIV-1 virus 
contains two positive-sense genomic RNAs that are stabilized by bound nucleocapsid (NC) 
proteins and encapsulated inside a conical capsid (CA) shell together with the reverse 
transcriptase (RT) and integrase (IN). The CA core is surrounded by a layer of matrix (MA) 
proteins associated to the lipid bilayer that contains the trimeric spikes composed of the 
envelope glycoproteins gp120 and gp41. These are essential for the attachment to the host 
and subsequent fusion with the cell membrane. The virus contains also the viral protease, 
which is essential for processing of the Gag, Gag-Pol and Env polyproteins and virus 
maturation. The respective processed viral proteins encoded by the gag, pol and env genes 
are indicated in purple, green and red brackets, respectively (Figure adapted from [35]). 
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Figure 3: Overview of the HIV-1 replication cycle. The infection begins when the envelope 
(Env) glycoprotein spikes engage the receptor CD4 and the membrane-spanning co-receptor 
CCR5 or CXCR4 (step 1), leading to fusion of the viral and cellular membranes and entry of 
the viral particle into the cell (step 2). Partial core shell uncoating (step 3) facilitates reverse 
transcription (step 4), which in turn yields the pre-integration complex (PIC). Following import 
into the cell nucleus (step 5), PIC-associated integrase orchestrates the formation of the 
integrated provirus, aided by the host chromatin-binding protein lens epithelium-derived growth 
factor (LEDGF) (step 6). Proviral transcription (step 7), mediated by host transcription factors, 
yields viral mRNAs of different sizes, the larger of which require energy-dependent export to 
leave the nucleus via host protein CRM1 (step 8). mRNAs serve as templates for protein 
production (step 9), and genome-length RNA is incorporated into viral particles with protein 
components (step 10). Viral-particle budding (step 11) and release (step 12) from the cell is 
mediated by ESCRT (endosomal sorting complex required for transport) complexes and is 
accompanied or soon followed by protease-mediated maturation (step 13) to create an 
infectious viral particle. Some of the cellular restriction factors (blue boxes) that limit HIV-1 
infection are indicated: TRIM5α blocks HIV-1 infection in many old world monkeys by 
interfering at the step of viral uncoating prior to reverse transcription, APOBEC3G is a cytidine 
deaminase that inhibits reverse transcription, SAMHD1 is a phosphohydrolase that depletes 
the pool of nucleotides available for reverse transcription by converting nucleotide 
triphosphates into a nucleoside and a triphosphate and Tetherin is a transmembrane protein 
that prevents virus release by cross-linking budded virions at the cell surface (Figure & Legend 
adapted from [33]). 
 
The viral envelope contains spikes that are composed of the glycoproteins gp120 and gp41, 
forming trimers of noncovalent heterodimers [36-38] (Figure 2). Gp120 binds to the cell-
surface receptor CD4 of different CD4+ leukocytes, in particular CD4+ T cells and 
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macrophages, and engages with an additional chemokine co-receptor, that is either CXCR4 on 
CD+ T cells or CCR5 on macrophages [39,40]. This triggers a cascade of conformational 
changes in the spike glycoproteins leading to fusion of the viral and host membranes [41-43]. 
The HIV-1 core, which contains reverse transcriptase (RT), integrase (IN) and two nucleocapsid 
(NC) bound plus-sense RNA genomes encapsulated by a conical shell of the viral capsid (CA) 
protein, is released into the host cytoplasm upon fusion with the cell membrane (Figure 2Figure 
3). Once inside the cell, the viral core is named reverse transcription complex (RTC) as 
exposure to cytosolic nucleotides initiates reverse transcription [34]. The RT reverse transcribes 
the single-stranded viral RNA into DNA while continuously digesting the RNA component of 
the RNA–DNA hybrids. The resulting single stranded DNA is then transformed into double-
stranded cDNA (dscDNA) by the host DNA polymerase [33]. As the RTC migrates towards 
the nucleus by dynein driven retrograde transport along microtubules, it progressively 
disassembles and reorganizes with various host proteins to form the pre-integration complex 
(PIC) [44-46] (Figure 3). The PIC that is composed of linear dscDNA, integrase, matrix (MA) 
protein and host proteins is then imported into the nucleus and becomes competent for 
integration into the host cell chromosome. At some point between viral entry and nuclear import 
uncoating of the CA core has to take place. Not much is known about the exact time point and 
location of viral uncoating, but it is well established that interference with timing of this 
essential process, e.g. by stabilizing or destabilizing the CA shell, critically impairs reverse 
transcription and all following steps [47]. 
The dscDNA is flanked by so-called long terminal repeats (LTR) which serve as sites of 
integration and promoter/termination regions [48]. Once the viral DNA has entered the nucleus 
it can either integrate into the host chromosomes or circularize as one or two long terminal 
repeat (LTR)-containing circles [46]. Although non-integrated viral DNA cannot produce 
viable particles, it can contribute to HIV-1 replication by generating RNA transcripts that 
increase activation of T-cells and render them more permissive to HIV-1 infection, e.g. through 
production of Nef protein [49-52]. Integration of the viral dscDNA into the host genome is 
carried out by the viral integrase. It nucleolytically processes the dscDNA at both LTRs 
generating recessed 3’ ends and ligates them to the 5’ phosphates of a double stranded cut in 
the cell DNA. Host enzymes complete the integration process by repairing the single-strand 
gaps at the viral 5’ends resulting in establishment of a stable provirus [33]. To target preferable 
sites of integration, the PIC associates with the host protein lens epithelium-derived growth 
factor (LEDGF). The chromatin-binding protein LEDGF is a transcriptional co-activator that 
binds integrase and promotes viral integration within active genes [53]. 
Depending on the host cell, the integrated provirus can either remain quiescent as in the case of 
resting CD4+ T cells or generate a persistent infection like in macrophages [54]. Latent pools 
of HIV-1 as achieved in resting CD4+ T cells constitute a major obstacle to eradication of the 
virus even in the presence of highly active antiretroviral therapy (HAART) [55,56]. Unless they 
are activated, these cells do not progress to complete viral replication, allowing the virus to hide 
from the host immune system and remain unaffected by current antiretroviral drugs. Immune 
activation of latently infected CD4+ T cells induces binding of host transcription factors to 
enhancer elements in the 5’ LTR promoter region [57]. Initial transcription output is, however 
very low and just sufficient to produce tiny amounts of the viral transactivator protein Tat. 
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Binding of Tat to the stem-loop trans-acting response element (TAR) in the 5’ region of viral 
transcripts is required for efficient elongation and synthesis of full-length HIV-1 mRNAs 
[58,59]. Viral mRNAs are produced as a variety of alternatively spliced species. The fully 
spliced (encoding Tat, Rev and Nef) and partially spliced (encoding Vif, Vpr and Env) mRNAs 
are readily exported from the nucleus, whereas the unspliced and singly spliced mRNAs 
(genomic RNA, also encoding Gag-Pol and Gag) require assistance by the viral Rev protein. 
Rev bridges the unspliced and partially spliced transcripts to the nuclear export machinery by 
binding both to Rev response element (RRE) of the viral mRNA and to the host nuclear export 
factor CRM1 [60,61] (Figure 3). 
Once in the cytoplasm, the viral genomic-length mRNA is translated into the precursor 
polyproteins Gag and Gag-Pol. Both precursors multimerize and are targeted to the cell 
membrane by myristoylation of the N-terminal matrix domain [62-64]. Gag and Gag-Pol are 
thus concentrated at phosphatidylinositol-4,5-biphospate rich lipid rafts at the inner cell 
membrane and assemble into virus-like particles [65,66]. In parallel, the trimeric envelope 
glycoprotein (Env) is recruited to the membrane through interactions with the matrix domain 
and two genomic RNA strands are packed into each virus-like particle by interacting with the 
zinc fingers in the NC domain of Gag. The NC-RNA interactions further contribute to the tight 
assembly of Gag and Gag-Pol [67]. Retroviral budding is coordinated by interactions of the 
Pro-rich late domains with cellular components of the class E vacuolar protein sorting (VPS) 
pathway, which normally act in the budding of cellular vesicles into late endosomes [68,69]. 
HIV-1 thus hijacks those VPS proteins to complete viral budding and release newly formed 
immature particles, which have a spherical morphology. Shortly after release, the viral protease 
(PR) is auto-activated and converts the immature particles into infectious virions by cleaving 
the Gag and Gag-Pol precursors into the structural MA, CA and NC proteins and the enzymes 
PR, RT, and IN [70]. Virus maturation is completed upon structural reorganization of these 
proteins and assembly of a conical CA core shell surrounding the NC-RNA complexes [71] 
(Figure 2). 
The antiretroviral restriction factor TRIM5 had been found to block infection in the early phase 
of the retroviral life cycle. More precisely, this block occurred after viral entry because HIV-1 
variants carrying the envelope protein from an unrelated virus (VSV-G), that would bypass 
blocks related to cell-surface binding, fusion and entry, were still inhibited by TRIM5 [72]. 
Also it had to occur before reverse transcription, because little or no linear dscDNA could be 
detected in restrictive cells [73]. Infectivity experiments with chimeric viruses in which 
components from a restricted virus were swapped with those from an unrestricted virus 
identified the viral CA protein as the determinant for virus susceptibility [24,74-76]. 
Quantitative separation of intact cytoplasmic virion cores from soluble CAs of HIV-1 infected 
cells (“faith of the capsid assay”) revealed a good correlation between TRIM5 restriction and 
loss of intact CA particles, suggesting that TRIM5 blocks retroviral infection through premature 
uncoating of the CA core prior to reverse transcription [77]. 
1.3 Domain Architecture of TRIM5 
TRIM5 is part of the tripartite motif (TRIM) containing family of proteins that comprises nearly 
100 human members [78]. The TRIM motif, also called RBCC, is characterized by the presence 
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of an N-terminal RING, followed by one or two B-Boxes and a CC domain which are conserved 
in relative order and spacing (Figure 4) [79]. The α splice isoform of TRIM5 has retroviral 
restriction activity and contains an additional C-terminal B30.2 domain harboring the 
determinants for virus specifity (Figure 4 A) [30]. In a few examples however, the B30.2 
domain has been replaced by CypA, another CA binding domain, during evolution (Figure 4 
B) [31]. 
None of the four TRIM5 domains is dispensable for full restriction activity and each of them 
adopts a different role in contributing to the proteins function. 
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Figure 4. Domain architecture of TRIM5 proteins. Available atomic structures of 
corresponding TRIM5 domains are shown below a conceptual scheme illustrating the domain 
composition in TRIM5 proteins. RING, B-Box and coiled-coil (CC) domains, characteristic of 
the RBCC motif, are colored in blue, green and red, respectively. The lack of structural 
information on the CC-L2 part of TRIM5 proteins is symbolized by a question mark. (A) TRIM5α 
possesses a C-terminal B30.2 domain (orange). The atomic structures of the RING and B-Box 
from human TRIM5α (pdb entries: 2ECV and 2YRG) and the B30.2 from rhesus TRIM5α (pdb 
entry: 2LM3) are shown in cartoon representation. (B) In TRIMCyp proteins, the C-terminal 
B30.2 domain has been replaced by a Cyclophilin A (CypA) domain (cyan, pdb entry 1AK4) 
during evolution. Due to the high sequence conservation in the RING and B-Box, these 
domains can be expected to share the same structure as in human TRIM5α. 
1.3.1 The RING E3-ligase domain 
The N-terminal RING domain of TRIM5 has E3-ligase activity and thus confers the ability to 
catalyze the formation of polyubiquitin chains [80]. As the name implies, ubiquitin is 
ubiquitously expressed inside the cell and the attachment of mono- or polyubiquitin chains to 
proteins expands their functional repertoire or controls their lifespan [81]. The consequences of 
ubiquitination include the regulation of many cellular events, such as protein degradation, 
protein trafficking, transcription, DNA repair, cell-cycle progression and apoptosis. Such a 
diverse outcome of ubiquitination is achieved through selective attachment of ubiquitin to 
protein substrates and interaction of the ubiquitin signal with a vast array of ubiquitin receptors 
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and modulators. To distinguishably communicate with more than 150 known ubiquitin 
receptors, the ubiquitin signal itself needs to be diverse. Thus, ubiquitin chains are variable 
length and linkage type, thereby providing selectivity for ubiquitin receptors [81]. 
Ubiquitination is achieved through an enzymatic cascade involving ubiquitin-activating (E1), 
ubiquitin-conjugating (E2), and ubiquitin-ligating (E3) enzymes [82]. E1 charges ubiquitin via 
a thioester bond with its catalytic cysteine in an ATP-dependent manner. This induces structural 
changes in E1 that promote binding to an E2 conjugating enzyme, to which ubiquitin is 
transferred [83]. Typically, the ubiquitin loaded E2 subsequently binds to an E3 ligase which 
passes the activated ubiquitin to its protein substrate. This usually results in the covalent 
attachment of the ubiquitin C-terminal glycine to a lysine ε-amino group of the protein 
substrate. Furthermore, ubiquitins can be linked to each other via any of its seven lysines and 
its N-terminal methionine providing variability of the formed ubiquitin chains. Different 
linkage positions result in different ubiquitin chain conformations, defining the specifity for 
ubiquitin receptors and downstream events. For example, Lys48-linked chains adopt a “closed” 
conformation with tightly packed ubiquitin subunits and target the substrate protein for 
proteasomal degragation. By contrast, Lys63-linked chains are extended and frequently interact 
with ubiquitin receptors that are involved in cellular signaling events. 
The human genome is estimated to encode two E1s, about 40 E2s and more than 600 E3 ligases 
[82]. In most cases it’s the pairing of E2 and E3 that determines both substrate specifity and the 
type of ubiquitin chain linkage, with the E2 having the major influence on the type of 
polyubiquitin chains formed and the E3 defining the ubiquitinated target substrate. 
E3 ligases are sub-characterized by the presence of RING (Really Interesting New Gene), 
HECT (homologous to the E6-AP carboxyl terminus) or U-box domains. E3-ligases containing 
a HECT domain are by themselves catalytically active and transfer ubiquitin from the E2 to the 
protein substrate by forming a thioester bonded intermediate via a catalytic cysteine. By 
contrast, the structurally similar RING and U-box domains only serve a scaffolding role in 
linking an E2 enzyme to a specific protein substrate without forming a covalent intermediate 
[81].  
The NMR structure of the human TRIM5α RING domain encompassing the first 78 N-terminal 
residues has recently been solved and features a characteristic ββα RING fold. However, the 
RING of TRIM5α contains shorter β-strands and a longer α-helix as compared to other typical 
RING domain structures (Figure 5 A) [84]. The domain coordinates two Zn2+ atoms 
tetrahedrally in a cross-brace conformation, with the first zinc finger being formed by four 
cysteines (CCCC finger) and the second zinc being coordinated by one histidine and three 
cysteines (CHCC finger) (Figure 5 B). By comparison to homologous RING domain structures, 
two functionally important surface regions were identified on the RING domain of rhesus 
TRIM5α. The first region defines a putative E2-binding patch that has a similar amino acid 
composition as in the E2-binding regions of Cbl, CHIP and cIAP2 RING domains [82]. The 
second identified region is located on the opposite side of the E2-binding patch and represents 
a putative RING-RING interaction surface that is similar to the interaction region in BCRA1 
and BARD1 RING heterodimers [85]. In some non-TRIM proteins, RING domains play the 
role of molecular scaffolds for the formation of supramolecular complexes by self-association, 
which in a few cases improves E3-ligase activity [86-89]. 
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Figure 5. The RING domain of human TRIM5α. (A) The NMR structure of the human TRIM5α 
RING domain (pdb entry: 2ECV) is shown in cartoon representation with coordinated zinc 
atoms as grey spheres. (B) Schematic representation of the RING-finger showing the cross-
brace coordination of the zinc atoms. 
 
TRIM5α has been reported to mediate self-ubiquitination by cooperating with the E2 ubiquitin 
conjugating enzyme UbcH5b both in vitro and in vivo [80,84,90]. A role for the RING mediated 
self-ubiquitination was found in the rapid turnover rate of TRIM5α inside the cell that occurs 
in an ubiquitin and proteasome dependent manner [91]. Moreover, TRIM5α degrades at a 
higher rate when cells are challenged with viruses bearing restriction-sensitive capsids, 
suggesting a mechanism where proteasomes are recruited to auto-ubiquitinated TRIM5α bound 
virus particles [92]. Indeed, TRIM5α biochemically interacts with the proteasome component 
PSMC2 as well as the proteasomal adaptor protein p62 and colocalizes with proteasomes in 
infected cells [93,94]. Deletion of the RING domain or disruption of its zinc finger by the 
C15A/C18A mutation leads to a major loss of restriction activity and much prolonged half-lives 
of TRIM5α [30,95,96]. Although proteasome inhibitors simultaneously lengthen TRIM5α half-
life and rescue viral reverse transcription as well, they do not eliminate restriction activity 
[97,98]. This apparent discrepancy might at least partially be explained by the fact that the 
RING domain is also required for the formation of higher-order self-assemblies and efficient 
CA binding [99]. However, a more detailed mutational study of the TRIM5α RING domain 
identified mutations in the putative E2 binding region that abrogated self-ubiquitination, but 
retained the ability of TRIM5α to self-associate and bind HIV-1 CA-NC tubes in vitro. These 
mutants did no longer block reverse transcription and showed a clear correlation between 
decreased ubiquitination activity and loss of restriction potency [84]. Interestingly, mutants of 
rhesus TRIM5α with substitutions at residue Tyr63 near the E2-binding cleft in the RING 
domain have lost the ability to block reverse transcription and fail to dismantle HIV-1 capsids 
in the faith of the capsid assay, but retain potent restriction of HIV-1 [100]. This phenotype 
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resembles more to the effect of proteasome inhibitors and suggests an additional redundant 
mechanism for TRIM5 mediated restriction that occurs after reverse transcription and prevents 
viral integration into the host genome. 
1.3.2 The B-Box self-association domain 
All TRIM proteins possess at least one, in some cases two B-Box domains. Based on differences 
in their zinc binding consensus motif and overall length, they are divided into B-Box type 1 (B-
Box1) and B-Box type 2 (B-Box2) domains. While the B-Box1 is only found in a few TRIMs, 
the B-Box2 is present in all of its family members known to date and is regarded the determinant 
of the TRIM family of proteins [101]. In general, B-Box domains have been implicated in 
protein-protein interactions and in some cases like e.g. TRIM5 mediate higher-order self-
association [102]. Atomic structures of B-Box1 and B-Box2 domains share a RING-like ββα 
fold and the similarity in tertiary structures suggests that these domains have evolved from a 
common ancestor gene [101-104]. In the crystal structure of TRIM63/MuRF1, the B-Box2 self-
associates into homodimers with their α-helixes binding into the hydrophobic groove formed 
by β-sheets on the opposite protomer [101]. Insight into the relative domain arrangement in 
TRIMs containing two B-Boxes is given by the solution structure of TRIM18/MID1 B-Box1 
B-Box2 tandem motif. Here, the two B-Boxes are forming a stable intramolecular interaction 
via an interface formed between the two domains, that is located on the opposite side of the B-
Box2 homodimer interface [105]. 
TRIM5 possesses a B-Box2 domain and the NMR solution structure has been solved for 
residues 86-131 encompassing the B-Box2 of human TRIM5. It features the characteristic ββα 
RING-like fold that is maintained by two zinc ions in a CHCDC2H2-type coordination mode 
with an additional very short β-strand just before the helix (Figure 6). Interestingly, the majority 
of hydrophobic residues are solvent exposed and clustered, forming two hydrophobic patches 
on the domain surface, cluster1 and cluster2. Mutations near or within cluster1, which 
corresponds to the dimerization interface found in TRIM63/MuRF1, impaired the ability of 
TRIM5α to self-associate without affecting dimerization. Higher-order self-association of 
TRIM5α contributes to the efficiency of binding to CA-NC tubes in vitro and correlates with 
potency of retroviral restriction [102]. Thus the B-Box2 domain is required for TRIM5α 
restriction activity and plays an essential role in enhancing TRIM5 avidity to the retroviral 
capsid by mediating higher-order self-association. 
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Figure 6. The B-Box2 domain of human TRIM5α. (A) The NMR structure of the human 
TRIM5α B-box2 domain (pdb entry: 2YRG) is shown in cartoon representation with coordinated 
zinc atoms as grey spheres. (B) Schematic representation of the zinc-fingers showing the 
coordination of the zinc atoms in a cross-brace manner. 
 
1.3.3 The coiled-coil (CC) dimerization domain 
TRIM proteins are predicted to contain a coiled-coil (CC) domain as part of their RBCC-motif 
(RING, B-Box and Coiled-Coil) [106]. CCs typically consist of two to five α-helixes that wrap 
around each other into a left-handed helix to form a supercoil [107]. Here each α-helix goes 
through 3.5 residues along the superhelical axis for each complete turn of the helix, whereas it 
is taking 3.6 residues per turn in regular α-helixes. This forces the helixes to intertwine against 
each other with a characteristic periodicity of seven residues (heptad repeat) occuring every two 
turns of the helix [108,109]. This repeat is usually denoted (a-b-c-d-e-f-g)n in one helix, (a’-b’-
c’-d’-e’-f’-g’)n in the next and so on, with positions a and d being hydrophobic core residues 
located in the interface between the bundled helices, e and g being exposed polar residues that 
give specifity between the helices through electrostatic interactions and the remaining three 
being hydrophilic solvent exposed residues [110] (Figure 7Figure 8). Due to this heptad pattern 
one nonpolar face is formed along each helix that facilitates oligomerization by packing of the 
hydrophobic side chains in a “knobs-into-hole” manner. This means that the hydrophobic side 
chains from one helix, such as the amino acid at position a (knob) binds into a hole formed by 
residues d’, g’, a’ and d’ + 1 heptad of the opposing helix [111]. The hydrophobic interactions 
are complemented by ionic interactions between charged residues at position e and g (Figure 
7). 
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Figure 7: Schematic representation of a parallel dimeric CC. The helical wheel diagram on 
the left shows residues of the heptad repeat pattern with their contributions to the CC α-helical 
assembly. The knob-into-hole packing of hydrophobic residues as well as the ionic interactions 
are shown on the right (figure taken from [107]). 
 
Subtle variations to the rules described above or changements in the type of hydrophobic and 
polar amino acids placed at position a, d or e, g, respectively determine the orientation, specifity 
and oligomerization state of the CC. Thus CCs can exist as parallel or anti-parallel homo- or 
hetero-oligomers and can vary in the extent of superhelical character due to shifts in the heptad 
pattern. A more dramatic shift in the repeat pattern is found in right-handed CCs: In these CCs 
the number of residues per turn is slightly increased to 3.67, thus giving a right-handed supercoil 
with eleven residues every three turns of the helix, forming a characteristic undecatad repeat 
pattern [112,113] (Figure 8). 
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Figure 8: Schematic representation of left- and right-handed CCs. (A) A heptad repeat in 
a regular α helix produces a left-handed hydrophobic stripe and a left-handed supercoil. This 
arrangement is schematically illustrated alongside the standard sevenfold helical wheel 
projection for coiled coils. (B) An undecatad repeat in a regular α helix produces a right-handed 
hydrophobic stripe and a right-handed supercoil. The 11-fold helical wheel projection is 
illustrated. H, hydrophobic residue; P, polar residue; +/−, charged residue (figure and legend 
taken from [112]). 
 
In TRIM5α, the predicted CC-domain is succeeded by a designated L2 linker region that 
connects to the C-terminal B30.2. Together, the CC and L2 confer low-order dimerization of 
the protein, which is indispensable for TRIM5α antiviral activity [114-119]. Alternative splice 
variants of TRIM5 that lack the B30.2 and sometimes other domains exert a dominant negative 
effect on retroviral restriction by higher-order associating with the alpha isoform, thereby 
down-regulating TRIM5 activity. Interestingly, splice variants or constructs that lack the CC 
domain fail to have any effect on TRIM5-mediated retroviral restriction [30,117,120,121]. 
From this point of view, the CC domain can be regarded the most crucial domain in TRIM5 
proteins. Not only does it mediate dimerization, but together with the L2 it additionally 
contributes to the ability to form higher oligomers, through a mechanism that is not known 
[99,119,122]. Residues in the L2 region of TRIM5α have been identified that do not interfere 
with dimerization, but lead to a loss of restriction [122].  To date the CC is the only domain in 
TRIM proteins, for which no structural information is available. 
1.3.4 The B30.2 capsid binding domain 
The longest TRIM5 splice variant, isoform alpha, is the only one conferring retroviral 
restriction activity and it is unique in bearing a B30.2 (or PRYSPRY) domain at its C-terminus. 
This domain has its name from the exon it was first identified in, exon B30-2 in the human 
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major histocompatibility complex (MHC) class I region [123]. The alternative name PRYSPRY 
comes from the independent identification of a closely related domain named SPRY in the splA 
kinase from Dictyostelium discoideum and in mammalian ryanodine receptors (RyR) [124]. 
Sequence alignments revealed that the SPRY domain shares a consensus motif with the C-
terminal part of the B30.2 domain. However, B30.2 domains have an additional N-terminal 
consensus motif that is not present in SPRY domains on a sequence level [125]. This extension 
is sometimes referred to as PRY (for SPRY associated domain), hence the name PRYSPRY 
that is synonymous with the B30.2 domain [126]. 
B30.2 domains are found in over 500 different proteins [127], including many that have later 
been identified as TRIM family members [123]. Indeed, the B30.2 domain is present in almost 
half of the TRIM proteins and the structures of several B30.2 domains have been solved. These 
include the structures from sRFPL1, TRIM5α, TRIM20/pyrin, TRIM21, TRIM25 and 
TRIM72/MG53 [126,128-133]. B30.2 structures share an identical fold composed of two layers 
of antiparallel β-sheets that stack together into a distorted β-sandwich with non-structured loops 
connecting the individual β-strands. TRIM5α differs slightly from other B30.2 domains due to 
the increased length and flexibility of its unstructured loops. This is in particular true for the 
longest loop v1, which was found to be highly dynamic and completely unhooked from the 
domains core structure as determined by a complementary structural study that combined NMR 
with X-ray crystallographic data [129] (Figure 9). 
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Figure 9: Structure of the rhTRIM5α B30.2 domain. The X-ray structure of the rhesus 
TRIM5α B30.2 domain with the most dynamic variable loop (v1) substituted by a two amino 
acid linker shown in cartoon representation and was supplemented with the NMR relaxation 
parameters of the variable v1 loop. The ten lowest-energy conformations of the v1 loop 
calculated using NOE restraints are shown as colored ribbons. The strands forming the beta 
sandwich B30.2 fold are numbered, and the variable loop regions (v1-v4) are labeled and 
highlighted in dark green (figure taken from [129]). 
 
Deletion of the B30.2 domain in several proteins, including TRIM5, abolishes the interaction 
with their respective binding partners suggesting that the B30.2 acts as a protein-interaction 
module [134]. Direct binding of TRIM5α to retrovirion CA cores is required for restriction and 
is mediated by the B30.2 domain. This has been demonstrated by co-sedimentation of TRIM5α 
either with detergent-stripped virion cores or with in-vitro assembled core-like CA particles 
[77,114,115,135,136]. Association of TRIM5α orthologs with retroviral CA particles correlated 
with respective restriction specifities and was dependent on the presence of the B30.2 domain 
[77,135]. In the case of TRIM5α, the B30.2 domain constitutes the main determinant for virus 
specifity and hybrid TRIM5α proteins with swapped B30.2 domains originating from orthologs 
of a different restriction specifity regain the respective restriction phenotype. For example cells 
expressing a chimeric TRIM5α composed of human RBCC domains fused to the rhesus B30.2 
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domain obtain the restriction phenotype of rhesus TRIM5α, thus becoming restrictive against 
HIV-1 [121].  
Overall, the B30.2 domain functions as a point of contact with the retroviral CA and 
manipulations that disrupt this interaction also disrupts TRIM5α restriction activity against that 
retrovirus [30,32,76,117,121,137-146]. 
1.3.5 Independent Evolution of a TRIMCyp fusion gene 
As already mentioned, a TRIM-cyclophilin A (TRIMCyp) fusion gene that confers potent HIV-
1 restriction activity was first discovered in new world owl monkeys, independent of the 
simultaneous discovery of TRIM5α in rhesus monkeys [31]. Cyclophilin A (CypA) in its free 
form is a ubiquitously expressed cytoplasmic protein that catalyzes cis/trans isomerization of 
peptidyl-prolyl bonds [147]. It acts as a co-factor for HIV-1 by binding to an exposed loop on 
the viral CA surface and promotes an early step of HIV-1 infection in human cells [147-156].  
Knock-down or inhibition of CypA by cyclosporine A (CsA) in target cells delays HIV-1 
replication [153,154]. CypA is incorporated into HIV-1 CA cores in a stoichiometric ratio of 
1:10 and has a measured affinity of KD = 16 µM for the isolated CA protein [157]. The 
relatively high affinity of CypA for the HIV-1 CA likely explains the potent HIV-1 restriction 
activity found in TRIMCyp expressing owl monkey cells. 
The TRIMCyp fusion gene in owl monkeys, carries all the hallmarks characteristic for LINE1-
mediated retrotransposition events, giving a likely explanation for the mechanism behind the 
insertion of a complete CypA cDNA into the TRIM5 locus [31]. In the case of owl monkeys, 
TRIMCyp is the only TRIM5 allele found in all ten species from the genus Aotus (owl monkeys) 
and phylogenetic analysis of these genes suggest a single retrotransposition event having 
occurred in a common ancestor several million years ago [31,144,158,159]. Though not as 
ubiquitous as in the Aotus species, a similar TRIMCyp fusion gene arose in the genus Macaca 
by convergent evolution and is found in at least three Macaca species [160-163]. As in Aotus, 
the Macaca fusion gene was most likely generated by the enzymatic machinery of a LINE-1 
element. However, they were clearly generated independently of the Aotus fusion gene, because 
the cDNAs encoding CypA are inserted at different positions into the TRIM5 locus: While in 
Aotus the CypA cDNA is inserted into TRIM5 intron 7 proceeding exon 8 encoding the B30.2 
domain, the Macaca CypA was retrotransposed just 3’ of exon 8 requiring a different splicing 
pattern to yield a functional TRIMCyp protein. In Macaca the 3’ splice acceptor site before 
TRIM5 intron 7 is disrupted, thus bypassing exon 7 and 8 and linking exon 6 to CypA by 
splicing to generate mRNAs encoding TRIMCyp [161]. Compared to Aotus, the Macaca 
TRIMCyp gene product is slightly shorter because it lacks exon 7 coding for the N-terminal α-
helix of the B30.2 domain. 
Introduction 
 
26 
 
 
Figure 10: Structure of the Aotus and Macaca TRIMCyp genes compared to TRIM5α. 
Diagram illustrating the splicing pattern of TRIM5α or TRIMCyp in New World monkey (NWM) 
Aotus and Old World monkeys (OWMs) Macaca. Non-coding and coding exons and cyclophilin 
A (CypA) sequences are shown in gray, black, and red, respectively (figure taken from [164]). 
 
Based on the Aotus TRIMCyp gene sequence, Neagu et al. have engineered a series of 
TRIMCyp fusions using human gene sequences, some of which potently restricted HIV-1. 
However, the exact positioning of the CypA insertion into the TRIM5 locus turned out to be 
very critical, as some of the engineered constructs failed to restrict HIV-1 [165]. Differences 
regarding the relative spatial arrangement of the CypA domains in the context of a TRIM5 
dimer may account for the different restriction phenotypes observed with the engineered 
TRIMCyp constructs. Therefore, it will be very interesting to gain insight into the structure 
function relationship of these constructs, once structural information on TRIM CC-L2 
dimerization domains is available. 
1.4 The Broad Restriction Spectrum of TRIM5 and Determinants for Viral 
Tropism 
Each TRIM5 ortholog ranging from human to various primate species recognizes and restricts 
a slightly different set of retroviruses in a species-specific manner. For example, TRIM5α from 
rhesus macaques inhibits HIV-1, EIAV, as well as FIV, while human TRIM5α only weakly 
inhibits HIV-1, but restricts infection by N-MLV and EIAV instead [32,137,138,141,166,167]. 
Remarkably, even TRIMCyp orthologs from Aotus or Macaca that harbor a C-terminal CypA 
as a CA binding domain instead of a B30.2 domain differ from each other in their respective 
restriction range for retroviruses: Whereas Aotus TRIMCyp recognizes HIV-1 and FIV, 
TRIMCyp bearing Macaca subspecies have evolved to restrict different subsets of retroviruses 
[162,163,168-170]. Macaca mulatta (rhesus macaque) TRIMCyp restricts HIV-2 and the O-
groups of HIV-1. In contrast, Macaca fasicularis TRIMCyp restricts HIV-1, FIV and SIVtan 
but not HIV-2, similar to Aotus.  
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It is subtle differences in the amino acid sequence of the B30.2 or CypA domains, such as non-
synonymous single nucleotide polymorphisms (nsSNPs) or small insertions that account for the 
inter-species differences in restriction specifities [142-144,171-174]. This is best illustrated by 
the fact that a single amino acid substitution, R332P, in the B30.2 domain of human TRIM5α 
is sufficient to confer potent anti HIV-1 restriction activity [145,146]. 
Altogether, TRIM5 orthologs have divergently evolved to restrict a broad range of retroviruses, 
spanning the families of spumaviruses, betaretroviruses, lentiviruses and gammaretroviruses 
[78]. The ability of a same TRIM5 ortholog to bind to various retroviral CAs and the minor 
changements required to switch restriction specifity towards different retroviruses transpires 
that different retroviral CAs share a common binding epitope recognized by TRIM5. While 
high-resolution structures are available both for retroviral CAs and the TRIM5 B30.2 domain, 
there is no direct structural information identifying the binding interface. However, by looking 
at residues under strong positive selection, determinants for restriction specifitiy or CA 
mutations that allow viruses to escape TRIM5 restriction, a glimpse into the putative binding 
epitopes can be gained. 
1.4.1 Determinants of antiviral specifity on the B30.2 domain 
As mentioned above, it is the C-terminal B30.2 domain that carries the determinants for virus 
specifity of TRIM5α. Sequence analysis comparing TRIM5α orthologs from different primate 
species has revealed four poorly conserved variable regions (v1 – v4) within the B30.2 domain 
that coincide with hot spots of positive selection through primate evolution [142,143]. Most of 
these sequence variations are clustered in a 13-amino-acid stretch comprising the longest 
variable loop v1 [142,143]. Experiments with chimeric rhesus-human TRIM5α proteins 
containing exchanged v1 regions have demonstrated that HIV-1 restriction specifity is largely 
determined by this variable hotspot [121,142,145]. These included the single amino acid 
substitution (R332P) in human TRIM5α that conferred potent HIV-1 restriction activity to this 
otherwise permissive ortholog. In contrast, spider monkeys have an expanded B30.2 v3 region 
in TRIM5α due to a tandem triplication that was found to be determinant for its broadened 
range of restricted viruses, including SIVmac, SIVagm, HIV-1 and N-MLV [144].  Mapping 
of specifity determinants for N-MLV restriction by human TRIM5α has also pointed out the 
importance of other variable regions besides the v1 (Figure 11 A) [175-177]. 
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Figure 11: Putative binding surface on the rhesus TRIM5α B30.2 domain. (A) Two views 
of the atomic structure of the rhesus TRIM5α B30.2 domain in cartoon representation. The 
variable loops (v1 –v4) that are determinant for virus specificity are colored in red and the 
domains core structure colored in green. (B) Altogether, the determinant regions for virus 
specificity make up for a large binding surface on the B30.2 domain (colored in red). The 
dimension of this surface are indicated by the arrow on the bottom. 
 
Inspection of the rhesus TRIM5 B30.2 structure reveals that the major differences between 
TRIM5α species of different virus specifities cluster on one surface of the B30.2 domain, 
comprising the longest variable loops [129,130]. These residues form a large surface predicted 
to span a distance of 45 Å up to 70 Å, likely covering more than just one molecule on the CA 
core [130]. This surface is formed by the variable loops and the β-sheet surface between them 
(Figure 11 B). Intriguingly, there is striking congruence between the positions of residues that 
influence capsid recognition in TRIM5α, antibody binding in TRIM21, and the occurance of a 
hereditary disease when mutated in TRIM20/pyrin and TRIM18/MID1 [78,178]. 
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1.4.2 Determinants on the CypA domain of TRIMCyp fusion proteins 
Human CypA and its interaction with the HIV-1 CA are well characterized and the crystal 
structure of CypA bound to the HIV-1 CA N-terminal domain has already been solved in the 
nineties [148,149,179]. CypA binds to residues G89 and P90 in a surface exposed loop on the 
HIV-1 CA surface, thereby promoting an early step in the infection of human cells [148-156]. 
This loop in the CA N-terminal domain is therefore termed as the CypA binding loop. 
Whereas Aotus TRIMCyp recognizes HIV-1 and FIV, as does the parental CypA protein, the 
restriction profiles of Macaca TRIMCyp orthologs differ from the set of viral CAs recognized 
by their parental CypA [162,163,168,169,180]. Several non-synonymous amino acid changes 
are found when the CypA domain of the fusion gene is compared with the parental Macaca 
CypA [134]. These single amino acid substitutions cause a switch in restriction specifity in the 
respective TRIMCyp variants bearing them (Figure 12). In M. mulatta and M. nemestrina 
(pigtail macaque) two amino acid changes are found, D66N and R69H. Structural analysis of 
the CypA domain from M. mulatta TRIMCyp revealed that these substitutions alter the 
conformational space of the cyclophilin active site loop encompassing residues 66 and 69 
[169,170,181]. The R69H mutation expands antiviral specifity by allowing an open binding site 
conformation and enabling binding to the CA of HIV-2, while maintaining the ability to hold 
the closed binding site conformation that allows binding and restriction of HIV-1. The second 
substitution D66N directs specifity away from M-group, while keeping the ability to restrict O-
group HIV-1 and HIV-2 thus maintaining the conformational flexibility (Figure 12 A,B) [181]. 
The CA of HIV-2 differ from HIV-1 mainly by bearing a CypA binding loop that is shorter by 
one residue. The shift of restriction specifity towards O-group HIV-1 is associated with the 
occurance of methionine, valine or isoleucine at CA position 88 that is preferentially found in 
O-group HIV-1 isolates [169]. Interestingly, like Aotus TRIMCyp, the M. fasicularis 
(cynomolgus macaque) TRIMCyp restricts HIV-1, FIV and SIVtan but not HIV-2 despites 
bearing the specifity enhancing R69H substitution. Here the substitution E143K that is located 
distant from the CypA active site has been found to cause a conformational change that is 
propagated to the active site loop and alters CA recognition towards M-group HIV-1 (Figure 
12 C) [78,170]. Remarkably, the occurrence of these specifity determining substitutions does 
not follow the macaque phylogenetic history, hinting that suggestive waves of infections with 
an unknown ancestral lenivirus has differentially affected the selection of TRIMCyp variants 
in the macaque subspecies (Figure 12 B). 
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Figure 12. Evolution of TRIMCyp in Asian macaques. (A) Conformational diversity 
conveyed by the mutations D66N and R69H in the TRIMCyp cyclophilin domain from Asian 
monkeys. This diversity enables TRIMCyp to simultaneously restrict HIV-2 and O-group HIV-
1 by switching between an “open” and a “closed” conformation. The CypA domain of M.mulatta 
TRIMCyp is shown in a gray surface representation. Bound HIV-2 and HIV-1 O-group derived 
CA peptides are shown in orange. (B) Dentogram illustrating the macaque phylogeny with the 
amino acid changes that have occurred. The restriction specificity of the TRIMCyp species 
variants is shown on the right. (C) X-ray crystal structure of the HIV-1 CA NTD (orange) in 
complex with M. fascicularis (Mafa) CypA (yellow) next to a detailed view of the active site. 
The detailed view shows a superposition of side chains from the M-type HIV-1 CA:human CypA 
complex (pdb entry: 1AK4) colored in green and the Cyp side chains from M. fascicularis CypA 
TRIMCyp colored in yellow with interacting residues from the HIV-1 CA CypA-binding loop 
colored in orange (Figure adapted from [78,170,181]). 
1.4.3 Determinants for TRIM5α sensitivity on the Retroviral Capsid 
Collectively, TRIM5α proteins restrict a surprising diversity of retroviruses, bearing capsids 
that are only distantly related, at least on the level of primary sequence [78]. For example human 
TRIM5α restricts both the murine lentivirus N-MLV and the equine gammaretrovirus EIAV 
[32,137,138,141]. The rhesus TRIM5α protein inhibits HIV-1, N-MLV, EIAV, as well as FIV 
with HIV-1 and EIAV CAs sharing as little as 25% sequence identity [137,138,166,182]. Thus, 
retroviral CAs must share common binding epitopes recognized by TRIM5α despite the 
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sometimes low sequence identity. Another conserved structural feature shared amongst 
retroviruses is the organization of CA molecules into a hexagonal lattice in the context of an 
assembled mature CA core [183]. The fact that TRIM5α requires an assembled CA for efficient 
binding supports the hypothesis that TRIM5 recognizes a lattice associated pattern on the CA 
surface [77,135]. A model whereupon the interaction between TRIM5α and the CAs is based 
on multiple low-affinity interactions at multiple points of contact in the CA lattice is supported 
by the existence of two similar clefts in the N-terminal domains of MLV and HIV-1 CA 
[136,184]. Residues that influence sensitivity to TRIM5α map into those two clefts (Figure 13). 
One cleft is formed by CA α-helices 4-6 in MLV and 4-7 in HIV-1 and contains determinants 
for viral tropism such as residue 110 that is determinant for N- or B-tropism, or residues 82 and 
117 that when mutated allowed B-MLV to escape restriction by the B-MLV tropic human 
TRIM5α(Y336A) v1-loop mutant [73,140,175,182,185,186]. Recently, efforts to construct a 
macaque-tropic HIV-1 have led to the identification of three amino acid substitutions in HIV-1 
Gag-CA (M96L/R100S/G116) that map into the same cleft [187]. HIV-1 clones bearing these 
mutations escaped restriction by rhesus TRIM5α suggesting that these amino-acids interact with 
rhesus TRIM5α. The second cleft is formed by the N-terminal β-strands and α-helix 6 in both 
MLV and HIV-1 CAs. This region is critical for N-MLV restriction by rhesus TRIM5α, as the 
L10W mutation that obscures the cleft prevents rhesus TRIM5α binding and allows the virus 
to escape restriction [182]. 
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Figure 13: Determinants for TRIM5α sensitivity on the N-termimal CA domains of HIV-1 
and MLV. The atomic structures of the HIV-1 and MLV CA NTDs are shown in cartoon 
representation inside the surface envelope. Residues in the NTDs of HIV-1 and MLV CA 
proteins that influence sensitivity to TRIM5α occupy two surface-exposed clefts. Residues 
mapping to the outer edge near the CypA binding loop are colored in red and residues in the 
cleft near the β-hairpin are colored in green. 
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Nevertheless, it is very difficult to predict the CA regions bound by TRIM5α, because residues 
influencing TRIM5 restriction cover virtually the whole accessible surface on the CA N-
terminal domain. Further insight into the mode of ligand binding by B30.2 domains can be 
gained by the B30.2 domain structures of sRFPL1, TRIM21 and the SPRY of GUSTAVUS that 
were crystallized with a bound ligand [128,178,188]. Although the B30.2 domains all use a 
similar epitope for ligand binding, the mode of interaction with their ligands differs 
considerably from each other: While sRFPL1 and GUSTAVUS both bind to a linear peptide, 
TRIM21 binds to the Fc-region of IgG via a complex interface including both the constant 
region 2 and 3 of the antibody’s heavy chain. Therefore it is well possible that the TRIM5 B30.2 
recognizes retroviral CAs by binding both to linear epitopes, such as the CypA binding loop, 
and to complex surfaces of the CA N-terminal domain. 
1.5 The Quaternary Lattice Structure of the mature HIV-1 Capsid 
Retroviral CA proteins share a conserved tertiary structure and arrange into hexagonal lattices 
to form a retroviral core surrounding the viral genome [183]. However, retroviral CAs assemble 
into cores of different morphologies. The preferred shapes adopted by retroviral CAs include 
cones (e.g. HIV), cylinders (e.g. Mason-Pfizer monkey virus (MPMV)), or spheres (e.g. MLV) 
[183]. The HIV-1 capsid is best described by a fullerene cone model, where CA molecules 
assemble into a curved hexagonal surface lattice that forms a closed shell by the incorporation 
of 12 pentamers [184,189-194]. Molecular dynamics simulations based on cryo-electron 
microscopic (cryo-EM) data of assembled HIV-1 CA particles and preexisting atomic-
resolution structures suggest that the fullerene cone is composed of 186 – 216 CA hexamers 
with five CA pentamers placed at the narrow end and seven CA pentamers at the wide end 
[191]. To understand how the drastically different curvatures required to achieve a conical 
shape are accommodated in the hexagonal CA lattice, the intermolecular interactions at all four 
interfaces critical for assembly need to be considered: the inter-hexamer CTD interfaces at the 
pseudo-two-fold and pseudo-three-fold axes, and the hexamer forming NTD-NTD and NTD-
CTD interfaces [191]. 
HIV-1 CA molecules primarily exist as stable dimers in solution and therefore constitute the 
starting unit for mature CA assembly, which is thought to occur de-novo during virus 
maturation. Semi-three-dimensional Monte Carlo simulations of the initial stages of HIV-1 CA 
self-assembly suggest that CA dimers first condense into trimers of dimers initiating the 
formation of disordered clusters, which nucleate lattice formation upon appearance of the 
hexamer unit within a cluster (Figure 14) [191,195]. 
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Figure 14. Monte Carlo simulation of HIV-1 CA assembly. The Monte Carlo simulation with 
CA interaction parameters as described in [191] reveals the initial steps of CA assembly. HIV-
1 CA molecules are depicted with the NTDs colored in red and the CTDs colored in grey. 
Snapshots of assembly during the simulation process are shown. (A) Prior to assembly, the 
HIV-1 CA molecules are present as dimers in solution. A trimer of three CA dimers is initially 
formed (highlighted by the blue triangle) (B) and following the appearance of a first hexamer 
(C) quickly grows into a full hexagonal lattice (D). (Figures are adapted from [191]). 
 
Molecular dymanics flexible fitting (MDFF) of atomic CA structures into the 8.6 Å resolution 
cryo-EM map of tubular HIV-1 CA assemblies revealed an almost invariant NTD hexamer that 
closely resembles to the crystal structure of a cross-linked CA hexamer (Figure 15). This 
structure shows that the NTD-NTD contacts are dominated by complex hydrogen networks 
involving coordinated water molecules and the CA hexamer is further stabilized by interlocking 
NTD-CTD interactions between neighboring protomers. The NTD hexamer is surrounded by a 
more variable girdle of CTDs, which connect adjacent NTD hexamers via CTD-CTD 
interactions. CA dimerization is mediated by CTD α-helix 9 forming homotypic interactions 
between CTDs. Three distinct CTD dimer conformations are observed in the MDFF model of 
helical CA tubes, with dimerization helix 9 crossing angles of 36°, 44° or 54°, possibly adapting 
to the relative orientation of hexamers along the three helical directions of tubular CA 
assemblies (Figure 15 A). Another important feature is the CTD trimer interface formed at the 
pseudo-three-fold axis between adjacent hexamers. This interface is formed by a patch of 
hydrophobic residues situated on one face of CTD α-helix 10 and is specific to the mature 
capsid, as these residues do not contact each other in maturation defective virions in which 
cleavage of the nucleocapsid is prohibited [191,196].  
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Figure 15. HIV-1 CA tubular assemblies and building blocks of the HIV-1 CA cone. (A) A 
cryo-EM image of recombinant A92E CA tubular assembly (scale bar, 100 nm) is shown on 
the left, with the electron density map of the A92E CA tube showing helical symmetry depicted 
in the middle. Yellow arrows indicate CA helix 9 located at the CTD dimer interfaces adjacent 
hexamers. On the right side is a schematic representation of the CA tubular assembly. The 
three helical directions of tubular CA assemblies (a-b, b-c and a-c) are highlighted in yellow. 
(B) X-ray structures of a disulfide linked A14C/E45C/W184A/M185A CA hexamer (pdb entry: 
3H47) as present in HIV-1 CA tubular assemblies and a disulfide linked 
N21C/A22C/W184A/M185A CA pentamer (pdb entry: 3PO5) as required to close the HIV-1 
CA cone. The structures are shown in surface representation on the top and in cartoon 
representation below. The NTDs are colored in blue and the CTDs are colored in orange. 
(Figures are adapted from [191], [114], [189], [190]). 
 
Formation of a HIV-1 CA fullerene cone requires the insertion of 12 CA pentamers to close the 
shell (Figure 16 A). The crystal structure of a pentameric HIV-1 CA mutant reveals subtle 
rearrangements of the NTD-NTD interactions compared to the quasi-equivalent hexameric CA 
structure (Figure 15 B) [189,190]. These minor differences are adopted by coordinated water 
molecules in the hydrogen-bonding network between the NTDs, as direct hydrophilic contacts 
are absent in either of the two structures [189,190]. The molecular dynamics simulation of a 
CA pentamer surrounded by five hexamers (pentamer-of-hexamers / POH) and comparison to 
the hexamer-of-hexamers (HOH) extracted from the helical CA tube model, illustratively 
demonstrates how CA pentamers induce a sharp increase in CA curvature at the point of 
insertion: POHs form a highly curved dome-like structure, while HOHs are just slightly bent 
(Figure 16 B) [191]. Differences in CA curvature are accommodated at the trimeric CTD 
interface, which is more closely packed in the POH compared with the HOH (Figure 16 C)  and 
even absent in the planar two-dimensional crystal of the assembled HIV-1 CA [191,197]. 
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Figure 16. Incorporation of curvature enhancing pentamers into the HIV-1 CA cone.  (A)  
Molecular dynamics equilibrated all-atom model of the HIV-1 CA cone (pdb entry: 3J3Q) 
comprising 216 CA hexamers (blue, NTD; orange, CTD) and 12 CA pentamers (green). (B) 
All-atom MD simulation of a CA pentamer surrounded by CA hexamers (POH). On the top is 
a surface representation of the POH viewed along the tube axis (NTD in green for the pentamer 
and blue for the hexamers with CTDs all in orange). Below is a comparison of curvatures 
between POH (orange) and HOH (blue). (C) Comparison of CTD trimer interfaces arising in 
HOH (light blue) and POH (orange and black). The three CTDs at the trimer interface are within 
the dashed circles. (Figures taken from [191]). 
 
Zhao et al. have shown that HIV-1 CA tubes cross-linked via introduced cysteines at the CTD 
trimer interface resist structural damage exerted by a truncated rhesus TRIM5α construct 
comprising the CC and B30.2 domains. By contrast, cysteine cross-linking at the hexamer 
interfaces did not prevent TRIM5 mediated CA damage, which results in the release of CA 
strings. Based on these findings, the authors conclude that TRIM5α engages at the inter-
hexamer interfaces, connecting adjacent hexamers while destabilizing the CTD trimer interface 
[114]. This goes in line with the observation that most residues that influence TRIM5α 
sensitivity map to the outer edges of the CA hexamer [73,140,175,182,185-187].  
1.6 TRIM5 Avidity for the Retroviral Capsid Lattice 
TRIM5α does not appreciably interact with monomeric or dimeric CAs, but readily engages 
with assembled virus-like CA particles [77,115,135]. While the rhesus TRIM5 B30.2 domain 
is sufficient for detectable co-sedimentation with assembled HIV-1 CA tubes, this interaction 
is greatly enhanced in the presence of the CC-L2 dimerization domain (CC-B30.2) and full 
avidity to the CA lattice is only achieved in the presence of all four domains of TRIM5α, with 
B-box and RING mediating higher-order oligomerization [84,99,102,114,115,130,136,198]. 
This relationship between TRIM5 domain composition and avidity for the CA lattice becomes 
obvious when comparing the concentrations of respective TRIM5 construct needed for efficient 
co-sedimentation with assembled CA tubes: It takes about 30–50 µM B30.2 domain, 1-10 µM 
CC-B30.2 dimer and only 0.15-0.5 µM TRIM5-21R chimera for significant co-sedimentation 
with comparable amounts of CA-NC (5–10 µM) or wild-type CA (60-70 µM) tubes 
[114,115,130]. These results demonstrate that CA recognition by TRIM5 not only requires an 
oligomerized retroviral CA, but also relies on oligomerization of TRIM5 itself. Nevertheless, 
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the real dimension of how TRIM5 oligomerization and self-association contributes to CA 
binding was only unveiled when Ganser-Pornillos et al. reported that recombinant rhesus 
TRIM5-21R spontaneously self-assembles into paracrystalline two-dimensional hexagonal 
arrays (Figure 17 A) [136]. TRIM5-21R assembly is further promoted upon binding to planar 
HIV-1 CA lattices resulting in the formation of a complementary TRIM5-21R lattice matching 
on top of the hexagonal HIV-1 CA array. Although both TRIM5-21R and HIV-1 CA form 
hexagonal lattices, their lattice dimensions differ considerably in size with inter-hexamer 
spacings of 315-355 Å and 90 Å for TRIM5-21R and HIV-1 CA, respectively (Figure 17 B). 
The projection density map generated from Fourier-filtered Cryo-EM images of TRIM5-21R 
2D-crystals displays regions of high density at the threefold and twofold symmetry axes 
connected by thinner regions of weaker density (Figure 17 A) [136]. 
TRIM5-21R lattice formation is dependent on CC mediated dimerization and B-Box mediated 
higher-order oligomerization, as kinetically trapped TRIM5-21R monomer and the R121E B-
Box cluster 1 mutant both fail to self-assemble into hexagonal arrays [136]. Other studies have 
also identified the L2 region and the RING domain as important determinants for higher-order 
self-assembly [84,99]. Modifications that interfere with TRIM5 self-assembly correlate in each 
case with decreased avidity for retroviral CA particles. By contrast, truncation of the B30.2 
domain in TRIM5 does not prohibit hexagonal lattice formation, although the efficiency of 
assembly is lowered resulting in the formation of smaller and less well ordered 2D-crystals 
[136]. Based on these findings, Ganser-Pornillos and colleagues have proposed a model of how 
individual TRIM5 molecules may arrange in the hexagonal lattice (Figure 17 C). In this model, 
the CC domains are located within the narrowest electron density regions linking the L2/B30.2 
and RING/B-Box domains that occupy regions of high density at the midpoint and the ends of 
each hexamer edge. Thereby, two parallel TRIM5 dimers that contact each other via L2/L2 
interactions are placed along each hexagon side forming tetramers that span the length of 180-
205 Å [136]. 
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Figure 17. Higher-order self-assembly of TRIM5-21R into a hexagonal lattice. (A) On top 
is a negative-stained EM image of a spontaneously formed TRIM5-21R lattice (scale bar, 100 
nm). The computed Fourier transform (inset) of the area inside the red circle shows a clear 
hexagonal order. Below is a projection density map generated from TRIM5-21R lattices in 
vitreous ice. (B) Fourier-filtered images of A14C/E45C/W184A CA-NC crystals alone (top) and 
TRIM5-21R crystals alone (bottom) illustrate the dramatic difference in unit cell size of the two 
lattices. (C) Schematic model of the HIV-1 fullerene cone surrounded by a putative TRIM5 
lattice. A possible arrangement of the TRIM5 domains in the hexagonal lattice is proposed 
based on the assumption that TRIM5 forms parallel dimers. (Figure adapted from [136]). 
 
The mechanism of template induced complementary lattice formation upon recognition of an 
assembled retroviral CA suggests that TRIM5 multimerization may align multiple B30.2 
domains over repeating binding sites on the hexagonal CA lattice, thus synergistically 
combining multiple low affinity interactions to achieve a high avidity towards restrictive virion 
cores. This indicates that TRIM5 likely employs “pattern recognition” to bind to hexagonal CA 
arrays, which are common to all retroviral CAs. 
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1.7 Scope of the Thesis 
The discovery of TRIM5 as the factor responsible for the HIV-1 resistance in rhesus macaques 
has unleashed a fury of publications, unveiling many aspects of TRIM5 function in retroviral 
restriction. Only a few years after discovery, it became well established that TRIM5 blocks 
retroviral infection at an early post-entry stage prior to reverse transcription by binding to 
invading CA cores and accelerating CA uncoating. It turned out that full restriction activity of 
TRIM5 requires all of its four domains, with the individual domains contributing differently to 
the proteins function: the B30.2 domain is required for CA binding, the CC domain mediates 
multimerization and the RING domain confers E3 ubiquitin ligase activity. However, at the 
beginning of this thesis the function of the B-Box domain was still unknown as well as the 
mechanism of how the TRIM5 domains cooperate to mediate retroviral restriction. At this point 
of time, existing knowledge on TRIM5 was almost exclusively founded on cell-based assays 
and the scarcity of insight into the molecular mechanisms of TRIM5 function was largely due 
to the lack of structural and in-vitro biochemical data on TRIM5 proteins. 
The first aim of this thesis was therefore to establish protocols for the production of recombinant 
TRIM5 proteins and their functional characterization using in-vitro biochemical assays. By 
screening of full-length TRIM5 orthologs fused to different N-terminal solubility tags we aimed 
to identify a construct that is solubly expressed in insect cells and allows the purification to 
sufficient amounts for in-vitro biochemical assays and crystallization trials. As described in the 
first publication “TRIM5 is an innate immune sensor for the retrovirus capsid lattice”, we 
established a protocol for the purification of full-length owl monkey TRIMCyp, which allowed 
the detailed characterization of its E3-ligase activity using in-vitro biochemical assays in a 
collaboration. The TRIMCyp purification protocol could also be adapted for the production of 
TRIM5α orthologs. 
The second aim was to characterize the interaction of rhesus TRIM5α with the HIV-1 CA and 
to identify the binding epitope on the HIV-1 CA lattice. This required the identification of new 
truncated TRIM5α constructs that are amenable to standard biochemical binding assays, as full-
length TRIM5 proteins are notoriously prone to aggregation. Furthermore we had to make the 
HIV-1 CA amenable to these binding assays, because TRIM5α binding is specific to assembled 
CA particles, which are present as large aggregates. Therefore we aimed to generate soluble 
oligomeric HIV-1 CAs that recapitulate individual interfaces of the assembled CA. The binding 
studies performed with the B30.2 domain of TRIM5α and interface mimics of the HIV-1 CA 
lattice are described in the second manuscript “Dissecting the HIV-1 capsid lattice into distinct 
TRIM5 binding units”. 
The final aim of the thesis was to gain structural information on the relative domain 
organization of TRIM5 proteins. The structure of a homologous TRIM20 fragment 
encompassing the CC-L2-B30.2 domains is described in the third manuscript “Overall 
architecture and mode of dimerization of TRIM proteins revealed by the TRIM20 structure”. 
Based on the atomic model of TRIM20 and available structures of individual TRIM5 domains 
we provide a model for the structure of full-length TRIM proteins. 
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3 Final Discussion 
Establishing protocols for the production of purified full-length TRIM5 proteins, which are 
unprecedented in harboring the wild-type RING domain, has opened the door to in-vitro 
characterization of the TRIM5 E3 ubiquitin-ligase activity. Using ubiquitin assays in a 
collaborative work with Pertel and colleagues, we demonstrated that TRIM5 cooperates with 
the heterodimeric E2 ubiquitin-conjugating enzyme Ubc13/Uev1a to catalyze the formation of 
unanchored K-63 linked ubiquitin-chains, which trigger TAK1 activation by 
autophosphorylation in-vitro. In the cell, TAK1 activation leads to the induction of innate 
immune signaling pathways. The link to retroviral restriction was made by showing that binding 
of owl monkey TRIMCyp to in-vitro assembled HIV-1 CA tubes stimulates the formation of 
K-63 ubiquitin chains in the ubiquitin assay. This was not the case when the interaction of 
TRIMCyp with the HIV-1 CA was disrupted by mutation or the inhibitor cyclosporine A (CsA). 
Thus TRIM5 proteins act as PAMP (pathogen associated molecular pattern) receptors by 
recognizing a pattern on the retroviral CA lattice. 
A first structural hint on how binding of the TRIM5 C-terminal domain to the viral CA may 
lead to an enhanced E3-ligase activity mediated by the N-terminal RING domain has been 
found by Ganser-Pornillos et al. [136]. They reported that binding of chimeric TRIM5-21R 
proteins to planar hexagonal HIV-1 CA-NC arrays stimulates TRIM5-21R self-assembly into 
a complementary hexagonal lattice. It transpires that TRIM5 lattice formation may be coupled 
to E3 ligase activity via conformational changes or proximity effects, as both activities are 
stimulated when interacting with the retroviral CA lattice. A comparable mechanism where 
formation of supramolecular complexes by self-association improves RING E3-ubiquitin ligase 
activity is known for Mdm2, a negative regulator of the p53 tumor suppressor. Compared to 
monomeric Mdm2, these supramolecular complexes have an increased ubiquitination activity 
in the presence of limiting Ubc5Hc amounts, suggesting that oligomerization of RING E3s may 
induce ubiquitin polymerization by providing a scaffold for the efficient recruitment of E2 
enzymes. 
To elucidate whether the RING domains are brought into proximity in hexagonal TRIM5 
arrays, the relative positioning of the TRIM5 domains in the lattice needs to be known. 
However, the resolution of the electron density map derived from TRIM5 paracrystalline arrays 
is not sufficient to determine the position of individual domains in the lattice [136]. To gain 
structural insight into the relative domain organization of TRIM5 proteins, we have taken 
extensive efforts to crystallize either full-length or N-terminally truncated TRIM5 proteins. But 
no diffracting crystals were obtained for any of these TRIM5 constructs. Instead, the atomic 
structure of a homologous TRIM20/pyrin C-terminal fragment encompassing the CC-L2, here 
termed CHS (central helical scaffold), and B30.2 domains could be solved independently. This 
structure reveals an antiparallel dimerization mode mediated by the elongated CHS domain 
with the B30.2 domains centrally positioned on top of the CHS. To verify whether TRIM5 
shares the same fold, we have performed SAXS measurements with a homologous human 
TRIM5 construct and have determined its low resolution shape. Measured SAXS curves are 
shown in the appendix of this thesis (Figure 22). Indeed, the TRIM20/pyrin crystal structure 
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fits relatively well into the SAXS envelope corresponding to the filtered average of ab-initio 
models (Figure 18 A). This suggests that TRIM5 and TRIM20/pyrin share the same overall 
domain organization. While the dimeric CHS domain matches only into the region spanning 
the maximal diameter of the SAXS envelope, the remaining volume in the probability map 
leaves conformational space for different orientations of the TRIM5 B30.2 domains (Figure 
18). Interdomain flexibility was also observed in SAXS measurements of the TRIM20/pyrin C-
terminal fragment and rigid body modelling based on the scattering curve revealed a large 
conformational space for different B30.2 domain orientations relative to the CHS. 
 
Figure 18. Docking of atomic structures into the averaged SAXS envelope of a human 
TRIM5α CHS-B30.2 fragment. The depicted SAXS envelope is the filtered average of 
Dammin refined ab-initio models generated from a pre-calculated Damaver probability map of 
the human TRIM5α CHS-B30.2 domains. (A) Docking of the TRIM20/pyrin CHS-B30.2 
structure into the TRIM5α SAXS envelope. The TRIM20/pyrin CHS and B30.2 domains are 
shown in orange and red ribbons, respectively. (B) The rhesus TRIM5α B30.2 structure 
(magenta ribbon, pdb entry: 2LM3) fitted into the TRIM5α SAXS envelope on top of the 
TRIM20/pyrin CHS domain (orange ribbon). Two possible orientations of the rhesus TRIM5α 
B30.2 domains are shown. 
 
Due to the antiparallel fold of the CHS domain, the preceding N-terminal RING and B-Box 
domains in TRIM proteins are placed distal apart at the extreme ends of the CHS. The 
availability of overlapping RING and B-Box domain structures from several TRIM proteins 
has allowed us to generate a stereotype full-length model for TRIM proteins containing the 
RING and B-Box domains from human TRIM5α (Figure 19). To evaluate whether the TRIM 
full-length model applies to published data on TRIM5, we inspected the model for accessibility 
of known functional patches expected to be surface exposed (Figure 19 B). Both cluster 1 on 
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the B-Box domain and the putative E2 interaction patch on the RING domain remain surface 
exposed in our full-length TRIM model. Cluster 1 is implicated in higher-order oligomerization 
and lattice formation by mediating homodimerization of B-Box domains. The E2-patch is 
expected to interact with the E2 ubiquitin-conjugating enzyme as mutations in this region 
impair E3-ligase activity without affecting higher-order self-assembly and maps with residues 
of the E2 interaction site in homologous RING domains. A large fraction of the residues in the 
designated RING-RING interaction region map into the modelled interface between the RING 
and B-Box domains. This region was named RING-RING by Lienlaf and colleagues because 
of the structural similarity to the RING-RING interaction region between BRCA-1 and 
BARD1. The interface between BRCA-1 and BARD1 also corresponds to the binding interface 
between B- Box1 and B-Box2 in the tandem structure of the MID1 B-Boxes, which was taken 
as a template for modelling of the TRIM5 RING and B-Box domains. This explains why the 
RING-RING patch maps into the interface between RING and B-Box in our TRIM model and 
the existence of such a RING/B-Box contact in TRIM5 remains to be proven. Mutation of 
residues in RING-RING surface of TRIM5 have been shown to impair higher-order self-
assembly and therefore restriction activity [84]. Another surface patch that forms an interface 
in our TRIM model is cluster 2 on the B-Box domain, which is formed by hydrophobic residues. 
In our model, these residues are buried between the B-Box and helix 2 on the outer edge of the 
CHS domain. Although mutational studies on cluster 2 are sparse, mutation of residues mapping 
to CHS helix 2 on the opposite side have been shown to impair TRIM5 restriction activity and 
could be important for the proper orientation of the B-Box domains. 
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Figure 19. Stereotype full-length TRIM model. The model is shown in top and side view. (A) 
Cartoon representation of the full-length TRIM model obtained by docking the modelled 
RING/B-Box domains of human TRIM5α docked onto the crystal structure of the TRIM20/pyrin 
CHS-B30.2 domains. The individual TRIM domains are colored according to the depicted color 
code. (B) Full-length TRIM model in surface representation with known functional patches 
highlighted according to the depicted color code. The CHS – B30.2 patch mediates 
tetramerization by forming contacts between the CHS and B30.2 domain of two TRIM20/pyrin 
dimers. 
 
The contacts in the crystal-packing of the TRIM20/pyrin C-terminal fragment suggest the 
existence of TRIM tetramers. These tetramers are formed by binding of the B30.2 domain into 
the elongated stretch between helix 3 and helix 4 of the CHS of a neighboring dimer. The 
functional relevance of the tetramer interface is further supported by mutations in the 
corresponding CHS - B30.2 patch of TRIM5α that abolish restriction activity [122,199] (Figure 
19 B). Our full-length TRIM model also allows the construction of tetramers without clashing 
of the modelled domains (Figure 20 A,B) and reveals the domain organization of TRIM5 in the 
hexagonal lattice (Figure 20 C). The inter-ring spacing in the hexagonal TRIM5-21R arrays 
reported by Ganser-Pornillos et al. amounts to 315-355 Å, which is significantly larger than the 
HIV-1 CA lattice spacing of 90 Å [136]. Therefore each hexagon side of the TRIM5-21R lattice 
is approximately 180-200 Å in length and fits well to the maximal diameter in the TRIM full-
length model (Figure 20 C). Placing of TRIM tetramers into the hexagon sides and connecting 
them to each other via homodimeric B-Box contacts allows the construction of a hexagonal 
lattice. The arrangement of the TRIM5 domains in this lattice suggests that enhancement of the 
E3 ligase activity upon CA binding and TRIM5 self-assembly may be induced by proximity 
effects as the RING domains join at the threefold lattice interfaces. As the TRIM5 RING is 
known to contribute to higher-order self-assembly, it may additionally involve rearrangements 
of the RING domains that would allow inter-dimer contacts in the lattice. 
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Figure 20. Model of the full-length TRIM tetramer revealing the domain arrangement in 
the TRIM5 lattice. (A) Two separated TRIM dimers are shown in the relative orientation as 
found in TRIM20/pyrin tetramers. The arrows indicate how the B30.2 domains bind to the 
extended stretch in the CHS domain of a neighboring dimer to form a tetramer. (B) Full-length 
TRIM tetramer as observed in the TRIM20/pyrin crystal packing. (C) A schematic drawing 
showing the dimensions of the reported hexagonal lattice formed by the TRIM5-21R chimera 
is depicted on the left and the currently proposed lattice model by Ganser-Pornillos et al. with 
tetramers of parallel arranged TRIM dimers placed at the hexagon sides is shown in the middle 
[136]. Shown on the right is the lattice model using the B30.2 dependent tetramer as observed 
in the TRIM20/pyrin crystal. The arrows indicate the flexibility of the B30.2 domains revealed 
by SAXS measurements of the TRIM20/pyrin C-terminal fragment. 
 
TRIM5α binds with a considerable affinity exclusively to the assembled CA core of restricted 
retroviruses and binding to isolated monomeric of dimeric CAs is very weak. Furthermore, both 
the E3 ligase activity and the efficiency of TRIM5-21R lattice formation are only stimulated 
upon presentation of an assembled retroviral CA lattice. Together with the discovery that 
TRIM5 proteins act as pattern recognition receptors by inducing an innate immune response 
upon recognition of a retroviral CA lattice, it transpires that TRIM5α binds to a complex epitope 
that is only presented in the context of an assembled CA lattice. Considering the size of the 
predicted binding surface in the atomic structures of the rhesus TRIM5α B30.2 domain, it 
becomes evident that this surface must cover multiple CA subunits in the hexagonal CA lattice. 
To elucidate which arrangement of CA molecules, and therefore which symmetric interface, is 
bound by TRIM5α in the HIV-1 CA lattice, we have generated a series of HIV-1 CA oligomers 
that mimic symmetric interfaces of the HIV-1 CA lattice. Together with newly engineered 
trimeric CAs, the gallery of available CA oligomers now includes mono-, di-, tri-, and 
hexameric CAs. The measurement of the binding affinities of the rhesus TRIM5α B30.2 domain 
to these building blocks of the HIV-1 CA lattice revealed that the NTD-linked trimeric CAs 
and hexameric CAs have an increased affinity compared to monomeric or wild-type dimeric 
CAs. Furthermore, the binding data from dual-focus FCS measurements of the interaction with 
the CA hexamer could not be fitted using a single binding site model, but fitted well using a 
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two binding site model instead. Based on these findings, we concluded that the inter-hexamer 
gap spanning two neighboring hexamers would constitute the most promising epitope on the 
HIV-1 CA lattice. This epitope involves two NTD subunits on one CA hexamer and one NTD 
subunit on the neighboring CA hexamer. With two of these three NTD subunits participating at 
the N-terminal trimer interface, this potential TRIM5α binding epitope is supported the best by 
our interaction data, as it would both explain the increased affinity for the NTD-trimer and the 
two binding sites on the CA hexamer suggested by the binding kinetics. 
The binding avidity of the TRIM5α B30.2 domains for the retroviral CA lattice is greatly 
enhanced upon lower-order and higher-order oligomerization of TRIM5α. Therefore it is 
important to consider the relative arrangement of the B30.2 domains in the context of TRIM5 
oligomers to gain an overall picture of how TRIM5 may bind to retroviral lattices. With the 
crystal structure of a TRIM20/pyrin in hands and the provided evidence that TRIM5α shares 
the same fold, we can estimate geometrical constrains imposed to the relative orientation of the 
B30.2 domains in dimers and tetramers of TRIM5. Placing the TRIM20/pyrin tetramer structure 
on top of the HIV-1 CA lattice provides a fist idea on the dimensions and distribution of the 
B30.2 binding epitopes on the HIV-1 CA lattice (Figure 21A). Due to the antiparallel 
dimerization of the CHS, the B30.2 domains are oriented in an antiparallel fashion relative to 
each other in the dimer as well as in the tetramer of TRIM20/pyrin. Interestingly, neighboring 
NTD-trimer interfaces as well as the inter-hexamer gaps in the HIV-1 CA lattice, which are 
suggested as potential TRIM5α binding epitopes in our CA interaction study, are oriented 
antiparallel relative to each other. Based on the geometrical restrains of a hypothetical TRIM5α 
tetramer, conceptual models on how TRIM5 may bind to the HIV-1 CA lattice are shown in 
Figure 21 B, C and D. 
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Figure 21. Conceptual models for binding of the B30.2 domains onto the HIV-1 CA lattice 
in the context of a TRIM5α tetramer. (A) Placing of the full-length TRIM tetramer model on 
top of the HIV-1 CA lattice (pdb entry: 3DIK). (B) Binding of the rhesus B30.2 domain (pdb 
entry: 2LM3) at the inter-hexamer gaps. The B30.2 domains are oriented antiparallel to each 
other as observed in TRIM20/pyrin tetramers. (C) Binding of the rhesus B30.2 domain (pdb 
entry: 2LM3) at the NTD-trimer interfaces. The B30.2 domains are oriented antiparallel to each 
other as observed in TRIM20/pyrin tetramers. (D) Binding of the rhesus B30.2 domain (pdb 
entry: 2LM3) at the inter-hexamer gaps with two B30.2 domains being fixed in an antiparallel 
fashion as the B30.2 domains in the TRIM20/pyrin tetramer interface. Compared to (B), the 
other two B30.2 domains are allowed to swing out as suggested by the SAXS measurements 
of TRIM20/pyrin and bind to an inter-hexamer gap of a different orentation. 
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4 Appendix 
 
Figure 22. SAXS data for the CHS-B30.2 fragment of human TRIM5α. (A) Experimental 
scattering curves taken for calculation of the SAXS envelope. The sample shows a tendency 
for interparticle attraction at higher protein concentrations. The sample at 1.5 mg/ml was 
collected freshly from size exclusion prior to SAXS measurement. (B) The Kratky-plot of the 
merged SAXS data set shows a typical curve for a two domain protein with interdomain 
flexibility, comparable to the corresponding plot for the SAXS data of the TRIM20/pyrin C-
terminal fragment. (C) The guinier plot of the merged data set shows linearity without signs of 
interparticle attraction. (D) Pair distribution function P(r) showing the distance distribution in 
the measured TRIM5α molecule. 
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